The heterobivalent (SSTR2/albumin) radioligand [


Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2024
Historique:
received: 25 06 2024
accepted: 08 08 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 23 9 2024
Statut: epublish

Résumé

Somatostatin type 2 receptor (SSTR2) radionuclide therapy using β

Identifiants

pubmed: 39310112
doi: 10.7150/thno.100091
pii: thnov14p5371
pmc: PMC11413788
doi:

Substances chimiques

Receptors, Somatostatin 0
Copper Radioisotopes 0
Radiopharmaceuticals 0
1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane 0
Heterocyclic Compounds, 1-Ring 0
Albumins 0
Acetates 0
Copper-67 0
Sstr2 protein, mouse 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5371-5387

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Auteurs

Martin Ullrich (M)

Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.

Robert Wodtke (R)

Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.

Florian Brandt (F)

University Hospital Carl Gustav Carus at the Technische Universität Dresden, Klinik und Poliklinik für Nuklearmedizin, Dresden, Germany.

Robert Freudenberg (R)

University Hospital Carl Gustav Carus at the Technische Universität Dresden, Klinik und Poliklinik für Nuklearmedizin, Dresden, Germany.

Jörg Kotzerke (J)

University Hospital Carl Gustav Carus at the Technische Universität Dresden, Klinik und Poliklinik für Nuklearmedizin, Dresden, Germany.

Susan Richter (S)

University Hospital Carl Gustav Carus at the Technische Universität Dresden, Institute of Clinical Chemistry and Laboratory Medicine, Dresden, Germany.

Klaus Kopka (K)

Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, University Cancer Center (UCC), Dresden, Germany.

Jens Pietzsch (J)

Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH